Thymosin Alpha-1 vs LL-37
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ta1, Zadaxin
Thymosin alpha-1 (sold as Zadaxin, generic name thymalfasin) is a 28-amino-acid peptide originally isolated from the thymus gland, the organ that trains your immune system. Unlike most peptides in this space, it is a real, approved drug in over 35 countries for chronic hepatitis B and as an immune booster, though it has never been approved by the FDA in the United States. It has one of the larger human evidence bases of any peptide here, with trials in tens of thousands of patients.
Also: Cathelicidin, CAP18
LL-37 is the only cathelicidin antimicrobial peptide humans make, a 37-amino-acid, positively charged, helical fragment cut from a precursor protein called hCAP-18. It is a frontline player in the innate immune system, part of the body's chemical defense against bacteria, viruses, and fungi. This is mainstream, heavily studied human biology, not a fringe research peptide, though LL-37 itself is not an approved drug.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Thymosin Alpha-1 | LL-37 |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Thymosin alpha-1 works as an immune modulator rather than a stimulant, meaning it tries to rebalance the immune system rather than simply rev it up. It signals through toll-like receptors, particularly TLR9 and TLR2, on dendritic cells, which are the immune system's messengers. That signaling pushes naive T cells toward a Th1 (pathogen-fighting) profile, boosts natural killer cell activity, and improves antibody responses. At the same time it can promote regulatory T cells via the IDO pathway, which is why it is described as restoring balance: it can both wake up a sluggish immune response and dampen a dangerously overactive one. | LL-37 carries a net positive charge and has a water-loving and fat-loving (amphipathic) structure, which lets it home in on the negatively charged membranes of bacteria and physically punch holes in them. But killing microbes directly is only half the job. It also acts as a signaling molecule: it neutralizes bacterial toxin LPS, calms or tunes the inflammatory response, recruits immune cells to wounds and infection sites, and helps skin re-grow and close over injuries. It is produced by skin, gut, lung, and other epithelial cells, plus immune cells like neutrophils. This dual role, direct antimicrobial plus immune coordinator, is why it is described as a multifunctional host-defense peptide. |
| Common Dosing | 1.6 mg twice weekly 2-3x weekly | 100-200 mcg daily Once daily |
| Administration | Subcutaneous injection | Subcutaneous injection or topical |
| Typical Duration | 6-12 months for hepatitis | Variable by protocol |
| Best Time to Take | Morning | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is one of the few peptides on this list with serious human trial data, but the results are mixed and worth reading honestly. Thymosin alpha-1 is approved and widely used for chronic hepatitis B, often alongside interferon, and decades of use give it a strong safety record across more than 30 trials and over 11,000 subjects. The standout area is sepsis, and the story there is a cautionary tale: the earlier ETASS trial (Critical Care, 2013) hinted at lower 28-day mortality (26 percent versus 35 percent), but the much larger, better-designed TESTS phase 3 trial (BMJ, 2025, 1,106 patients, double-blind and placebo-controlled) found no mortality benefit at all (23.4 versus 24.1 percent). It has also been studied as an add-on in certain cancers and in vaccine response, with weaker evidence. The honest summary: real drug, good safety, proven in hepatitis B, but several of its most-hyped uses did not survive a rigorous trial. | The basic biology of LL-37 is well established across many peer-reviewed studies. Its broad antimicrobial activity, membrane-disrupting mechanism, and tissue distribution are documented in reviews such as those in the Journal of Leukocyte Biology and PMC-indexed updates on how it limits the spread of local infection. Research has also explored more speculative directions: LL-37 and engineered mimics have shown anticancer activity in laboratory models, and it has been studied as a possible host-defense factor against Helicobacter pylori in the stomach and against pathogens on the surface of the eye. The important honesty point is that almost all of this is mechanistic and preclinical. LL-37 is firmly proven as a natural part of human immunity, but as a deliberately administered therapy it has not cleared large human clinical trials, and its dual nature means it can also drive inflammation in some disease states. So: rock-solid as biology, still experimental as a treatment. |
Frequently Asked Questions: Thymosin Alpha-1 vs LL-37
What is the difference between Thymosin Alpha-1 and LL-37?
Thymosin Alpha-1 is a immune peptide that thymosin alpha-1 (sold as zadaxin, generic name thymalfasin) is a 28-amino-acid peptide originally isolated from the thymus gland, the organ that trains your immune system. unlike most peptides in this space, it is a real, approved drug in over 35 countries for chronic hepatitis b and as an immune booster, though it has never been approved by the fda in the united states. it has one of the larger human evidence bases of any peptide here, with trials in tens of thousands of patients. LL-37 is a immune peptide that ll-37 is the only cathelicidin antimicrobial peptide humans make, a 37-amino-acid, positively charged, helical fragment cut from a precursor protein called hcap-18. it is a frontline player in the innate immune system, part of the body's chemical defense against bacteria, viruses, and fungi. this is mainstream, heavily studied human biology, not a fringe research peptide, though ll-37 itself is not an approved drug. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Thymosin Alpha-1 or LL-37?
Neither is universally "better" - the choice depends on your specific goals. Thymosin Alpha-1 is typically used for immune purposes, while LL-37 is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Thymosin Alpha-1 and LL-37 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Thymosin Alpha-1 and LL-37 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.